Evidence-based approach to early outpatient treatment of SARS-CoV-2 (COVID-19) infection.
J Drew PayneKimberly SimsCynthia PeacockTanis WelchRuth E BerggrenPublished in: Proceedings (Baylor University. Medical Center) (2021)
Misinformation and promotion of well-intended but disproved therapies for COVID-19 have plagued evidence-based shared decision-making throughout the COVID-19 pandemic. In times of crisis, clinicians may feel that their strong inclination to prescribe potentially harmful, unproven therapies on behalf of their patients is supported by beneficence. Clinicians should mindfully identify and avoid commission bias during this pandemic, especially as more data have accumulated to assist with clinically sound decision-making. We describe a more evidence-based approach to treatment of early outpatient COVID-19, stressing the availability of Food and Drug Administration emergency use authorization therapies and considering plausibly beneficial, nonprescription supplements that are generally regarded as safe.
Keyphrases
- sars cov
- coronavirus disease
- end stage renal disease
- respiratory syndrome coronavirus
- public health
- decision making
- ejection fraction
- chronic kidney disease
- healthcare
- prognostic factors
- social media
- peritoneal dialysis
- patient reported outcomes
- machine learning
- risk assessment
- climate change
- big data
- smoking cessation
- replacement therapy